Robotic or open superficial inguinal lymph node dissection as staging procedures for clinically node negative high risk penile cancer.

Clinically node negative Inguinal lymph node dissection Penile cancer Penile squamous cell carcinoma Robotic Staging

Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
21 Feb 2024
Historique:
received: 24 11 2023
revised: 27 01 2024
accepted: 29 01 2024
medline: 23 2 2024
pubmed: 23 2 2024
entrez: 22 2 2024
Statut: aheadofprint

Résumé

To evaluate perioperative and oncologic outcomes of a cohort of clinically node negative high-risk penile cancer patients undergoing robotic assisted inguinal lymph node dissection (RAIL) compared to patients undergoing open superficial inguinal lymph node dissection (OSILND). We retrospectively reviewed the clinical characteristics and outcomes of clinically node negative high-risk penile cancer patients undergoing RAIL at MDACC from 2013-2019. We sought to compare this to a contemporary open cohort of clinically node negative patients treated from 1999 to 2019 at MDACC and Moffit Cancer Center (MCC) with an OSILND. Descriptive statistics were used to characterize the study cohorts. Comparison analysis between operative variables was performed using Fisher's exact test and Wilcoxon's rank-sum test. The Kaplan-Meier method was used to estimate survival endpoints. There were 24 patients in the RAIL cohort, and 35 in the OSILND cohort. Among the surgical variables, operative time (348.5 minutes vs. 239.0 minutes, P < 0.01) and the duration of operative drain (37 vs. 22 days P = 0.017) were both significantly longer in the RAIL cohort. Complication incidences were similar for both cohorts (34.3% for OSILND vs. 33.3% for RAIL), with wound complications making up 33% of all complications for RAIL and 31% of complications for OSILND. No inguinal recurrences were noted in either cohort. The median follow-up was 40 months for RAIL and 33 months for OSILND. We observed similar complication rates and surgical variable outcomes in our analysis apart from operative time and operative drain duration. Oncological outcomes were similar between the two cohorts. RAIL was a reliable staging and potentially therapeutic procedure among clinically node negative patients with penile squamous cell carcinoma with comparable outcomes to an OSILND cohort.

Identifiants

pubmed: 38388244
pii: S1078-1439(24)00052-8
doi: 10.1016/j.urolonc.2024.01.036
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Manuel Ozambela (M)

Department of Urology at The University of Texas MD Anderson Cancer Center, Houston, TX.

Barrett Z McCormick (BZ)

Department of Urology at The University of Texas MD Anderson Cancer Center, Houston, TX.

Jan K Rudzinski (JK)

Department of Urology at The University of Texas MD Anderson Cancer Center, Houston, TX.

Alberto C Pieretti (AC)

Department of Urology, Cleveland Clinic Florida, Weston, FL.

Graciela M Nogueras González (GMN)

Department of Biostatistics at the University of Texas MD Anderson Cancer Center, Houston, TX.

Matthew A Meissner (MA)

Department of Urology at The University of Texas MD Anderson Cancer Center, Houston, TX.

John N Papadopoulos (JN)

Department of Urology at The University of Texas MD Anderson Cancer Center, Houston, TX.

Mehrad Adibi (M)

Department of Urology at The University of Texas MD Anderson Cancer Center, Houston, TX.

Surena F Matin (SF)

Department of Urology at The University of Texas MD Anderson Cancer Center, Houston, TX.

Aaron S Dahmen (AS)

Department of Urology at University of Chicago, Chicago, IL.

Philippe E Spiess (PE)

Department of Genitourinary Oncology at Moffit Cancer Center, Tampa, FL.

Curtis A Pettaway (CA)

Department of Urology at The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: cpettawa@mdanderson.org.

Classifications MeSH